LaNova Medicines and Junshi Biosciences Enter into Multiple Combo Clinical Collaborations

Shanghai, October 23, 2021 - LaNova Medicines announced that it has recently signed an agreement with Junshi Biosciences, a leading domestic biopharmaceutical company. According to the agreement, LaNova Medicines will collaborate with Junshi Biosciences in multiple mutually beneficial clinical trials to test different combination therapies for cancer.

Regarding the strategic partnership, Dr. Crystal Qin, Chairman and CEO of LaNova Medicines, said: "This is a win-win alliance based on the strategy of combination therapies for the cancer treatment. We are full of expectations for the prospects of these clinical trials. We will continue to expand the collaboration scope to meet more clinical unmet needs."

About LaNova Medicines:

About LaNova Medicines: LaNova Medicines is a clinical stage biotech company founded by industry veterans. The company has the full-chain new drug research and development capabilities covering early research and development, translational medicine, and clinical development, and has received strong support from multiple leading investors. Based on its multiple R&D platforms, LaNova Medicines has created an innovative biologics drug pipeline with "first-in-class" and "best-in-class" potential and has successfully advanced multiple innovative drug products into clinical stage in China, U.S. and Australia.

About Junshi Biosciences:

Founded in December 2012, Junshi Biosciences (688180.SH, 1877.HK) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. The company has a rich R&D pipeline consisting of 44 products, covering five major therapeutic areas, including malignant tumors, autoimmune diseases, chronic metabolic diseases, nervous system diseases and infectious diseases.

Relying on the core platform technology of protein engineering, Junshi Biosciences is at the forefront of global biologics drug research and development. It has received the approvals of the first domestic anti-PD-1 monoclonal antibody NDA application and a domestic anti-PCSK9 monoclonal antibody IND application from China NMPA, as well as the world's first IND approval for anti-BTLA blocking antibody from China NMPA and US FDA,

In 2020, Junshi Biosciences also joined hands with domestic scientific research institutions to fight the COVID epidemic. The jointly developed JS016 has entered clinical trials as the first anti-COVID monoclonal neutralizing antibody in China, and has obtained emergency use authorization in 15 countries and regions around the world, contributing to disease prevention and control in China and the world with local innovation. At present, Junshi Biosciences has more than 2,500 employees around the world, distributed in San Francisco and Maryland in the United States, and Shanghai, Suzhou, Beijing and Guangzhou in China.